Price reference for Teclistamab in foreign markets

Teritusumab (Teclistamab-cqyv) is an innovative treatment drug for multiple myeloma (MM) . Although it has been approved for marketing in China, it has not yet been included in the medical insurance list, and patients have to pay higher out-of-pocket costs. In the domestic market, each box of teritusumab is priced at approximately RMB 30,000 to RMB 40,000. The specific price is affected by the drug specifications and supply channels. In overseas markets, teritusumab is also characterized by high prices. Common specifications of its original drug in the European market include 30mg/3ml and 153mg/1.7ml (90mg/ml). The former sells for about more than 10,000 yuan per box, and the latter may sell for more than 50,000 yuan per box. The price fluctuates with exchange rates and regional differences.

Currently, there are no generic drugs of teritusumab at home or abroad, and patients can obtain the original drug through formal channels to ensure efficacy and safety. The high price of drugs reflects their research and development costs, innovative mechanisms, and clinical value. As a bispecific T cell-engaging antibody, teritusumab is significantly more precise and effective in activating the immune system than traditional chemotherapy drugs, which also makes its market pricing at a high level.

The cost of teritusumab needs to be calculated based on the patient's treatment cycle, weight and medication frequency. For example, a once-weekly maintenance dosing regimen or a low-frequency dosing regimen once every two weeks will directly affect the patient's monthly medication expenses. In addition, short-term hospital observation in the escalating dose phase will also increase initial medical costs. Because it is designed for patients with refractory multiple myeloma, the clinical benefits of the drug can often be reflected by prolonging progression-free survival and improving the complete response rate. From an economic point of view, the high price is supported by the efficacy to a certain extent.

In short, the price of teritusumab is relatively high both at home and abroad, but its innovative mechanism, precise targeting of tumor cells, and clinical value in improving quality of life make it an important treatment option for patients with refractory multiple myeloma.

Reference materials:https://www.tecvayli.com/